This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Haas NB , Manola J , Hudes G , Citrin DL , Kies MS , Davis TE
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer
Am J Clin Oncol. 2000 Dec;23(6) :589-92
PMID: 11202803 URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11202803
AbstractTwenty-nine patients with progressive hormone-refractory metastatic adenocarcinoma of the prostate were treated with daily estramustine phosphate at 10 mg/kg, and I.V. doxorubicin 50 mg/m2 every 3 weeks. Twenty-six patients were evaluable. Four of seven patients with nonosseous measurable disease had partial responses lasting 3 to 10 months. Eleven of 19 patients with osseous metastases had stable disease or improvement on bone scan, 6 of these for 7 months or longer. Median time to progression was 20 weeks, and the median survival was 43 weeks.
Notes21071567 0277-3732 Clinical Trial Clinical Trial, Phase II Journal Article